Headquartered in Waltham, MA, EyePoint is a publicly-traded, specialty pharmaceutical company focused on ophthalmology. The company is led by CEO Nancy Lurker, who brings decades of experience successfully launching and commercializing new products. EW’s investment enabled EyePoint’s acquisition of a recently-approved product, DEXYCU, a steroidal injection following cataract surgery that can replace the burdensome steroidal drops used as the standard of care today. EyePoint also received FDA approval for its pipeline product YUTIQ, a three-year posterior uveitis implant, in October 2018. In addition to launching these two products, EW is working with the company to execute on a broader buy and build strategy within the ophthalmology space to capitalize on the management team’s commercialization expertise and drive value creation.
- o In March 2018, EW made a transformative investment in EyePoint, investing $9.5M to facilitate the acquisition of its lead asset DEXYCU. EW also negotiated to invest an additional $45M through the purchase of common shares and warrants at a pre-determined price to support the launch costs of DEXYCU and EyePoint’s pipeline product, YUTIQ
o EW has upgraded EyePoint’s board and is working diligently to execute on a “buy and build” thesis to create the next leading ophthalmology company